( August 4, 2026, 2:52 PM EDT) -- WASHINGTON, D.C. — Considering a patent dispute between Pfizer Inc. and other biopharmaceutical companies for the second time, a Federal Circuit U.S. Court of Appeals panel affirmed a U.S. Patent Trial and Appeal Board (PTAB) finding that Pfizer’s proposed substitute claims for a patent describing pneumococcal vaccine technology would be unpatentable as obvious....